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Abstract
Introduction: Osteoarthritis (OA) is a complex, multifactorial joint disease affecting both the cartilage and the
subchondral bone. Animal models of OA aid in the understanding of the pathogenesis of OA and testing suitable
drugs for OA treatment. In this study we characterized the temporal changes in the tibial subchondral bone
architecture in a rat model of low-dose monosodium iodoacetate (MIA)-induced OA using in vivo micro-computed
tomography (CT).
Methods: Male Wistar rats received a single intra-articular injection of low-dose MIA (0.2 mg) in the right knee
joint and sterile saline in the left knee joint. The animals were scanned in vivo by micro-CT at two, six, and ten
weeks post-injection, analogous to early, intermediate, and advanced stages of OA, to assess architectural changes
in the tibial subchondral bone. The articular cartilage changes in the tibiae were assessed macroscopically and
histologically at ten weeks post-injection.
Results: Interestingly, tibiae of the MIA-injected knees showed significant bone loss at two weeks, followed by
increased trabecular thickness and separation at six and ten weeks. The trabecular number was decreased at all
time points compared to control tibiae. The tibial subchondral plate thickness of the MIA-injected knee was
increased at two and six weeks and the plate porosity was increased at all time points compared to control. At ten
weeks, histology revealed loss of proteoglycans, chondrocyte necrosis, chondrocyte clusters, cartilage fibrillation,
and delamination in the MIA-injected tibiae, whereas the control tibiae showed no changes. Micro-CT images and
histology showed the presence of subchondral bone sclerosis, cysts, and osteophytes.
Conclusions: These findings demonstrate that the low-dose MIA rat model closely mimics the pathological
features of progressive human OA. The low-dose MIA rat model is therefore suitable to study the effect of
therapeutic drugs on cartilage and bone in a non-trauma model of OA. In vivo micro-CT is a non-destructive
imaging technique that can track structural changes in the tibial subchondral bone in this animal model, and
could also be used to track changes in bone in preclinical drug intervention studies for OA treatments.
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Osteoarthritis (OA) is generally a slow progressive joint
disease characterized by loss of articular cartilage, sub-
chondral bone sclerosis, cysts, and osteophyte formation
[1]. The etiopathology of OA remains obscure and cur-
rently there are no pharmacological interventions avail-
able to halt or reverse the progression of OA. Animal
models of OA are of considerable importance as they
are not only useful to study the pathogenesis and pro-
gression of OA, but also to evaluate suitable therapeutic
drugs for OA treatment. Moreover, knowledge of early
pathological changes is essential for early treatment
options and to develop better therapeutic agents to
modify the disease progression.
The monosodium iodoacetate (MIA)-induced OA rat
model is a minimally invasive animal model that repro-
duces cartilage and bone pathology similar to human
OA [2]. The onset, progression and severity of OA can
be easily controlled in this model by changing the dose
of MIA, which makes it useful to study disease progres-
sion and the effect of disease modifying osteoarthritis
drugs (DMOAD). A dose response study by Guingamp
et al. showed that the severity of cartilage degradation
depends on the dosage of MIA injected into the knee
joint. Higher doses of MIA (up to 3 mg) caused cartilage
erosion, sclerosis and exposure of subchondral bone on
day 15 post MIA injection, and on day 30 there was
complete loss of articular cartilage, with greatly remo-
delled subchondral bone [3], whereas, a low-dose of
MIA (0.25 mg) induced moderate cartilage damage at 3
weeks [4]. In a pilot study, we evaluated the dose
responsiveness of tibial cartilage and subchondral bone
to MIA using a high-dose of 2 mg MIA (n =3 )a n da
low-dose of 0.2 mg MIA (n = 3) in rats. As early as
after two weeks, high-dose MIA induced characteristic
features of end-stage human OA such as loss of tibial
articular cartilage, exposure of subchondral bone, sub-
chondral trabecular bone erosion, cysts and osteophytes.
In contrast, these changes were observed only at ten
weeks in the low-dose MIA model (Mohan G et al:
unpublished observations). The low-dose MIA model, of
relatively slow progressing OA, enables in vivo monitor-
ing of tissue-level changes representative of progressive
human OA; whereas, in the high-dose model the disease
progression is very rapid, which is less suitable for longi-
tudinal monitoring of cartilage and subchondral bone
changes.
The tissue-level characterization of animal models of
OA has traditionally been done by histological assess-
ment. Developments in X-ray micro-computed tomogra-
phy (micro-CT) allow in vivo imaging of small animal
models, with high spatial resolution and at subsequent
time points, to study bone architecture [5-7]. This
imaging technique enables non-destructive assessment
of the bone both quantitatively and qualitatively. More-
over, the use of a longitudinal study design using in vivo
micro-CT allows the quantification of subchondral bone
in the same animal over time. Recent studies have used
micro-CT to quantify structural changes in the tibial
subchondral bone in the MIA rat model; however, those
studies have utilized high-dose MIA injections, with the
rats examined only at the end point of the studies
[8-10]. The temporal changes in the structure of sub-
chondral trabecular bone during the progression of OA
in the low-dose MIA model have not been previously
described.
The purpose of this study was to characterize the
structural changes in the tibial subchondral bone using
longitudinal in vivo micro-CT imaging in an animal
model that closely mimics human progressive OA. It is
hypothesised that low-dose MIA will induce cartilage
changes and measurable, progressive tibial subchondral
bone changes at two, six, and ten weeks post-injection.
Materials and methods
Animals and OA induction
Twelve 8-week-old male Wistar rats (Animal Resource
Center, Canning Vale, WA, Australia), weighing 200 -
2 3 0ga tt h es t a r to ft h ee x p e r i m e n t ,w e r eu s e d .T h e y
were kept in a sanitary ventilated animal room with
controlled temperature (20 to 24°C), a light-dark cycle
( 1 2h o u r / 1 2h o u r )a n dw e r ef e ds t a n d a r dl a b o r a t o r y
rodent chow (Specialty Feeds, Glen Forrest, WA, Aus-
tralia) with water available ad libitum. The rats were
acclimatized for one week before the start of the experi-
ment. They were closely monitored and daily clinical
record sheets were completed throughout the duration
of the study by the animal care facility staff.
On day 0, the rats were anesthetized with an isoflur-
ane/O2 m i x t u r ea n db o t ht h e i rk n e e sw e r es h a v e da n d
disinfected with 70% alcohol. Each rat was given a single
intra-articular injection of 0.2 mg MIA through the
infrapatellar ligament of the right knee. MIA was dis-
solved in sterile physiologic saline and administered in a
volume of 50 μl using a 26-gauge 0.5-inch needle. The
left contralateral control knee was injected with 50 μlo f
sterile physiologic saline.
The hind limbs of all the rats were imaged with high-
resolution in vivo micro-CT at two, six, and ten weeks
post-MIA injection, which represent early, intermediate,
and advanced stages of OA. Double-fluorescent labelling
of newly formed bone was achieved by using calcein (5
mg/kg body weight; Sigma-Aldrich, Sydney, NSW, Aus-
tralia) administered intraperitoneally on day 7 before
sacrifice, followed by xylenol orange (90 mg/kg body
weight; Sigma-Aldrich, Australia) administered
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Page 2 of 14intraperitoneally 2 days before sacrifice. The animal
handling and experimental procedures outlined in this
study were carried out in accordance with The Univer-
sity of Adelaide Animal Ethics Committee and The
Institute of Medical and Veterinary Science Animal
Ethics Committee.
In vivo micro-CT imaging
In vivo micro-CT imaging was performed using a
bench-top cone-beam type in vivo animal scanner (Sky-
scan model 1076, Skyscan, Kontich, Belgium) [6]. Each
rat was anesthetized with isofluroane/O2 and placed in
the scanner bed in a supine position (Figure 1). The
MIA-injected knees and the contralateral control knees
were scanned separately. During each scan only the
knee for image data acquisition was irradiated, while the
contralateral limb and the rest of the body were lead-
shielded from radiation. The hind limb of the rat was
secured into a customized leg fixative device consisting
of a cylindrical plastic holder fitted to a polystyrene
tube. This allowed positioning of the hind limb close to
the central scanner axis, preventing any movement of
the limb during scanning. The total scan time for each
limb was 20 minutes during which the rat was under
anesthesia. The scans were performed using the follow-
ing scanner settings: X-ray source voltage 60 kVp, cur-
rent 100 μA, a 1-mm thick aluminum filter to reduce
beam-hardening artefact, 1 frame averaging. The pixel
size was 8.7 μm, the exposure time was 4.7 seconds, and
the rotation step was 0.8°, with a complete rotation over
197° [6]. The cross-sectional images were reconstructed
using a filtered back-projection algorithm (NRecon, V
1.4.4, Skyscan, Kontich, Belgium). For each scan, a stack
of 1,800 cross-sections was reconstructed, centered over
the knee-joint (total reconstructed height about 16 mm),
with an interslice distance of 1 pixel (8.7 μm). The
reconstructed images were of 1,500 × 1,500 pixels each,
8.7 μm pixel size, and were stored as 8-bit images (256
grey levels) [6].
Bone histomorphometric analysis
Subchondral trabecular bone
On the stack of the reconstructed micro-CT cross-sec-
tion images, manual regions of interest (ROI) of an irre-
gular anatomical contour were drawn in the
subchondral trabecular bone region for the medial and
lateral tibial plateau (Figure 2), for both the MIA-
injected knee and the control knee (software CT Analy-
ser, V 1.8.05, Skyscan, Kontich, Belgium). The volume
of interest (VOI) consisted of a stack of ROIs drawn
over 52 cross-sections, resulting in a height of 0.45 mm.
The VOI included the subchondral trabecular bone
starting below the subchondral plate, and extending dis-
tally towards the growth plate, excluding both the corti-
cal bone and growth plate interface. The VOI used was
o ft h es a m es i z ea n ds h a p ef o ra l lt h et h r e et i m ep o i n t s
(two, six and ten weeks), for both the control and the
MIA-injected tibia. For the calculation of the morpho-
metric parameters, the images were segmented using a
uniform threshold as described in a previously published
paper [6]. The following three-dimensional (3D) mor-
phometric parameters were calculated for the medial
VOI, the lateral VOI and the total (= medial + lateral)
VOI of subchondral trabecular bone (software CT Ana-
lyzer, Skyscan): bone volume (BV, mm
3), bone volume
fraction (BV/TV, %), trabecular thickness (Tb.Th, μm),
Figure 1 In vivo micro-CT imaging of a rat hind limb;
anaesthetized rat on the scanner bed in supine position, with
the hind limb secured in a customised leg fixative device
(inset). Micro-CT, micro-computed tomography.
Figure 2 Axial micro-CT image of a rat tibia, with the region of
interest (solid red line) in the medial (M) and lateral (L)
subchondral bone compartment. Micro-CT, micro-computed
tomography.
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ber (Tb.N, 1/mm). BV is the volume in 3D of the struc-
ture segmented as bone, and BV/TV is the ratio of the
segmented bone volume to the total volume of the
region of interest. Tb.Th is the mean thickness of the
trabeculae, Tb.Sp is the mean distance between trabecu-
lae, Tb.N is the average number of trabeculae present
per unit length. Tb.Th and Tb.Sp were assessed using
direct 3D methods, Tb.N was calculated using the for-
mula Tb.N = (BV/TV)/Tb.Th [6,11,12].
Subchondral plate
In the binarized images, the subchondral plate was sepa-
rated from the trabecular bone of the tibia by using a
software kindly provided by Botter et al. [13]. The 3D
subchondral plate thickness (Pl.Th, μm) and porosity
(volume of the pores in the plate over the total volume
of the plate, Pl.Por, %) of the medial and lateral com-
partments of the tibial subchondral plate were calculated
on regions measuring 1.5 mm medio-lateral in width,
2.5 mm in length from the posterior side. For both para-
meters (Pl.Th and Pl.Por), the data from the medial and
lateral compartments were averaged to obtain the value
of the total compartment [13].
Macroscopic analysis
At ten weeks post-MIA injection the rats were eutha-
nized with a CO2 overdose and both the right and left
tibiae were dissected for macroscopic study. Soft tissues
surrounding the tibia were carefully removed to prevent
articular cartilage damage. The image of the tibial carti-
lage was recorded using a fluorescence stereomicroscope
(SZX 10, Olympus). With the microscope, the fluoro-
chrome labels calcein and xylenol orange were imaged
and recorded. The macroscopic lesions were graded as
follows: 0 = normal appearance, 1 = slight yellowish dis-
coloration of the chondral surface, 2 = little cartilage
erosions in load-bearing areas, 3 = large erosions
extending down to the subchondral bone, and 4 = large
erosion with large areas of subchondral bone exposure
[3]. Two blinded observers graded the medial and lateral
tibial plateaus separately. The scores for the tibiae were
combined and the average values were determined for
the MIA-injected knee and the control knee.
Histological analysis
After imaging, the tibiae (n = 6 rats; tibiae from the
other 6 rats were used in another analysis) were fixed in
4% paraformaldehyde, decalcified and embedded in par-
affin. Three coronal sections (5 μm thick) 100 μma p a r t
were obtained and stained with 1.5% Safranin O, and
0.02% fast green counter stain. The sections were
observed for OA-like features such as surface disconti-
nuity, loss of proteoglycans, disorientation of
chondrocytes, subchondral bone sclerosis and presence
of cysts and osteophytes.
The Osteoarthritis Research Society International
(OARSI) scoring method [14] was used to grade and
stage tibial cartilage in the MIA-injected knee and con-
trol knee. For each histological slide, the OA score was
obtained by multiplying the grade and stage values. The
OA score ranges from 0 (representing no OA activity)
to 24 (highest OA degradation).
Serum C-reactive protein (CRP) analysis
Blood samples were obtained by tail venipunture from
the MIA-injected rats (n = 6) and a group of age-
matched control rats (n = 4, from another non-micro-
CT imaging study) under isofluroane anaesthesia. Blood
samples were obtained from the rats at pre-injection,
two, six, and ten week time points. Serum samples were
collected and stored at -80°C until analyzed. Serum
levels of CRP, a marker of systemic inflammation, were
measured by enzyme-linked immunosorbent assay
according to the manufacturer’sp r o t o c o l( R a tC R P
ELISA kit, BD Biosciences, San Diego, CA, USA).
Statistical analysis
The morphometric parameters had a normal distribu-
tion (Shapiro-Wilk test, P > 0.05 for all the examined
parameters). For each morphometric parameter it was
determined whether there was (a) a ‘time effect’ and (b)
a ‘time by group interaction effect’.T h e‘time effect’
indicates if there was any change over time within each
group (tibia of control and MIA-injected knee) and the
‘time by group interaction effect’ indicates if the differ-
ent groups showed different patterns of changes over
time. For each tibia, 3D morphometric parameters and
serum CRP data sets were examined using analysis of
variance for repeated measures (two-way repeated mea-
sures ANOVA). If F-values for a given variable were
found to be significant, a paired Student’st - t e s tw a s
applied to assess the changes in the morphometric para-
meters and CRP between the MIA-injected knee and
control knee. The P-values were adjusted for repeated
comparisons by Holm’s Bonferroni stepdown procedure
[15]. Similarly, a paired Student’st - t e s tw i t hP-values
adjusted for repeated comparison by Holm’s Bonferroni
stepdown procedure was done to assess changes in each
tibia between time points. The overall type I error rate
was set at an alpha level of 0.05.
Results
Micro-CT
Bone histomorphometric changes
The ‘time effect’ was significant for all the parameters.
The ‘time by group interaction effect’ was significant for
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nificant increase in total BV, BV/TV, Tb.Th, Tb.N, and
Pl.Th. in the tibial subchondral bone of both the MIA-
injected knee and the control knee over time (P < 0.05,
Figure 3). This was due to the natural growth of the ani-
mal. The total Tb.Sp of both the control tibia and the
tibia of the MIA-injected knee were significantly
decreased at ten weeks compared to two weeks (P <
0.001, Figure 3).
Subchondral trabecular bone
Table 1 shows the summarized data and comparison of
the tibial subchondral trabecular bone microarchitec-
tural parameters of the MIA-injected knee and the con-
trol knee at two, six, and ten weeks post-MIA injection.
At two weeks there was a significant decrease in BV and
BV/TV in the MIA-injected tibia compared to the con-
trol tibia, in both the medial and the total compart-
ments (-18% and -14%, respectively, P < 0.05 for both
parameters). However, at six and at ten weeks post-MIA
injection, although not statistically significant, there was
an increase in tibial subchondral trabecular BV and BV/
TV in the MIA-injected knee compared to the control
knee, particularly in the medial compartments (19% for
BV and BV/TV at 6 weeks and 26%, 19%, for BV and
BV/TV at 10 weeks, respectively).
At two weeks, no statistically significant difference was
observed in Tb.Th in all the three tibial compartments
between the MIA-injected knee and control. However,
at six and ten weeks, there was a significant increase in
Tb.Th in the MIA-injected knee compared to the con-
trol knee in the medial (25%, P < 0.001, and 35%, P <
0.01, respectively), lateral (23%, P < 0.01, and 22%, P <
0.05, respectively) and total (24%, P <0 . 0 0 1 ,a n d2 9 % ,P
< 0.01, respectively) tibial compartments. The Tb.N was
significantly lower in the MIA-injected knee compared
to the control knee in all the three tibial compartments
at two weeks and in the lateral and total compartments
at ten weeks post-MIA injection. At 2 weeks, the Tb.N
was reduced by 20% (P < 0.01), 12% (P < 0.05), and 16%
(P < 0.01) in the medial, lateral and total compartments,
respectively. At six weeks, the Tb.N did not differ signif-
i c a n t l yb e t w e e nt h et i b i ao ft h eM I A - i n j e c t e dk n e ea n d
control knee. At 10 weeks, the Tb.N was decreased by
14%, 16% (P < 0.01) and 15% (P < 0.05) in the medial,
lateral and total compartments, respectively, when com-
pared to the control knee. The Tb.Sp in the MIA-
injected knee was significantly higher than in the control
knee at all the three time points, in all the three tibial
compartments. At 2 weeks, the Tb.Sp of the MIA-
injected knee was increased by 11% (P < 0.001), 6% (P <
0.01) and 8% (P < 0.001) in the medial, lateral and total
compartments, compared to control. Similarly, at 6
weeks, in the MIA-injected knee there was an increase
of 18%, 13% and 16% (P < 0.01 for all compartments),
respectively, and at 10 weeks there was an increase of
16% (P < 0.01), 16% (P < 0.001) and 14% (P <0 . 0 1 ) ,i n
the medial, lateral and total compartments, respectively,
compared to control.
Subchondral plate
T h et i b i a ls u b c h o n d r a lp l a t et h i c k n e s so ft h eM I A -
injected knee increased significantly at two weeks (P <
0.01 for medial compartment) and six weeks (P <0 . 0 1
for both medial and total compartments) post injection
compared to the control knee. At ten weeks there was
no significant difference in thickness (medial, lateral or
total) between the MIA-injected knee and the control
knee (Table 2). The porosity of the tibial subchondral
plate was significantly increased in the MIA-injected
knee compared to the control knee at all time points in
all the three compartments analyzed (P < 0.01).
Qualitative subchondral bone changes
All the rats showed pathological subchondral bone
changes in the MIA-injected knee, whereas the contral-
ateral control knee showed no OA-like changes in the
tibial subchondral bone microarchitecture throughout
the study duration (ten weeks). Morphologic evaluation
of the MIA-injected knee over time showed sclerosis in
the tibial subchondral bone at six and ten weeks after
MIA injection, particularly in the medial tibial condyle
(Figure 4). At six and ten weeks, the tibial subchondral
plate of the MIA-injected knee was breached in focal
areas, these breaches were confirmed by histology (Fig-
ure 5A, B). From the micro-CT images, in 8 out of 12
rats (67%), empty spaces were observed in the medial
tibial subchondral bone of the MIA-injected knee at 6
and 10 weeks. These empty spaces were confirmed as
cysts from the histology sections (Figure 5C, D). Mar-
ginal osteophytes were observed in all the rats at six and
ten weeks from the micro-CT images and these osteo-
phytes were confirmed by histology (Figure 6). Three-
dimensional surface rendering of the MIA-injected knee
showed erosion and pitting of the tibial subchondral
plate, which was more severe in the medial tibial pla-
teau, whereas the control knee maintained the subchon-
dral plate integrity (Figure 7).
Macroscopy
All the rats developed cartilage lesions in the tibia of
MIA-injected knees. At ten weeks, the tibial cartilage of
the MIA-injected knee showed focal lesions with yellow
discoloration indicating cartilage degradation (Figure
8A, D). This was more prominent in the central region
of the medial tibial plateau, whereas cartilage degrada-
tion remained at a moderate stage on the lateral side,
giving a total joint grade of 3.16 ± 0.75 (mean ± SD).
Macroscopically, the control tibia showed no cartilage
lesions in the medial and lateral tibial plateau (joint
grade 0). Significant calcein and xylenol orange labels
Mohan et al. Arthritis Research & Therapy 2011, 13:R210
http://arthritis-research.com/content/13/6/R210
Page 5 of 14Figure 3 Plots of morphometric parameters of subchondral trabecular bone determined by micro-CT in the control tibiae and in the
MIA-injected tibiae, at two, six, and ten weeks post-MIA injection. There was a statistically significant increase over time in BV, BV/TV, Tb.Th,
and Tb.N, and a decrease in Tb.Sp, in both the control and MIA-injected tibiae. Error bars = SD. BV, bone volume; BV/TV, bone volume fraction;
CT, computed tomography; MIA, monosodium iodoacetate; TB.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness. * P
< 0.05, ** P < 0.01, *** P < 0.001, between control tibiae and MIA-injected tibiae.
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Page 6 of 14Table 2 Tibial subchondral plate thickness and porosity of the MIA-injected knee and control knee, at 2, 6, and 10
weeks post-MIA injection.
Subchondral Plate Thickness, Pl.Th (μm) Subchondral Plate Porosity, Pl.Por (%)
Medial Lateral Total Medial Lateral Total
%d %d %d
OA Control p-
value
OA Control p-
value
OA Control p-
value
OA -
CTL
p-
value
OA -
CTL
p-value OA -
CTL
p-value
2
weeks
114 ±
7
105 ± 7 0.027 101 ±
6
109 ± 7 0.305 107 ±
4
107 ± 8 0.770 23 0.004 24 0.004 24 0.003
6
weeks
146 ±
32
119 ±
32
0.024 130 ±
17
120 ±
26
0.880 138 ±
23
118 ±
26
0.028 63 0.001 69 p <
0.001
66 p <
0.001
10
weeks
181 ±
27
175 ±
31
0.520 166 ±
18
178 ±
24
0.318 177 ±
19
177 ±
25
0.473 66 0.004 77 0.004 71 0.003
Data represented as mean ± SD for plate thickness, % d is the percentage difference in plate porosity between the control and MIA-injected knee. MIA,
monosodium iodoacetate; OA, osteoarthritis; OA-CTL, osteoarthritis control; SD, standard deviation
Table 1 Morphometric parameters of tibial subchondral trabecular bone in the MIA-injected tibiae and in the control
tibiae, at 2, 6, and 10 weeks post-MIA injection
2 Weeks 6 Weeks 10 Weeks
OA Control %d p-value OA Control %d p-value OA Control %d p-value
Mean ±
SD
Mean ±
SD
OA-
CTL
Mean ±
SD
Mean ±
SD
OA-
CTL
Mean ±
SD
Mean ±
SD
OA-
CTL
BV (mm
3)
Medial 613 ± 97 745 ± 118 -17.8 0.018 1177 ±
211
993 ± 214 18.6 0.102 1481 ±
271
1179 ±
229
25.6 0.102
Lateral 647 ± 120 711 ± 130 -9.0 0.116 1145 ±
168
948 ± 169 20.7 0.116 1229 ±
133
1205 ±
241
2.0 0.709
Total 1260 ±
202
1456 ±
239
-13.5 0.048 2322 ±
341
1941 ±
370
19.7 0.098 2710 ±
326
2384 ±
454
13.7 0.116
BV/TV (%)
Medial 16.8 ± 2.6 20.4 ± 3.2 -18.0 0.018 32.7 ± 6.5 27.5 ± 6.6 19.1 0.156 39.8 ± 7.7 33.6 ± 7.6 18.5 0.156
Lateral 15.1 ± 2.8 16.7 ± 3.0 -9.1 0.156 27.2 ± 3.6 22.2 ± 3.8 22.5 0.156 29.0 ± 3.2 28.2 ± 6.0 3.0 0.592
Total 15.9 ± 2.5 18.6 ± 3.0 -14.0 0.032 30.0 ± 4.2 24.8 ± 5.0 20.6 0.154 34.4 ± 4.8 30.9 ± 6.4 11.5 0.156
Tb.Th (μm)
Medial 94 ± 5 92 ± 3 2.1 0.396 124 ± 11 100 ± 9 24.6 p <
0.001
149 ± 19 110 ± 12 34.9 0.001
Lateral 89 ± 4 87 ± 3 1.6 0.360 117 ± 9 95 ± 5 23.1 0.001 128 ± 17 105 ± 8 22.0 0.012
Total 91 ± 4 90 ± 3 1.9 0.396 120 ± 9 97 ± 7 23.9 p <
0.001
138 ± 18 108 ± 10 28.6 0.002
Tb.N (1/
mm)
Medial 1.8 ± 0.3 2.2 ± 0.3 -19.9 0.009 2.5 ± 0.5 2.7 ± 0.5 -9.5 0.405 2.6 ± 0.5 3.1 ± 0.4 -13.7 0.112
Lateral 1.7 ± 0.3 1.9 ± 0.3 -12.2 0.020 2.2 ± 0.3 2.3 ± 0.3 -6.8 0.405 2.3 ± 0.3 2.7 ± 0.3 -16.0 0.009
Total 1.7 ± 0.2 2.1 ± 0.3 -16.3 0.009 2.3 ± 0.3 2.5 ± 0.4 -8.3 0.405 2.5 ± 0.3 2.9 ± 0.4 -14.8 0.012
Tb.Sp (μm)
Medial 270 ± 16 243 ± 17 10.8 p <
0.001
240 ± 19 203 ± 24 17.9 0.002 241 ± 32 207 ± 20 16.3 0.005
Lateral 272 ± 16 256 ± 17 6.2 0.001 250 ± 16 221 ± 14 13.2 0.001 258 ± 17 223 ± 15 15.7 p <
0.001
Total 271 ± 13 250 ± 14 8.4 p <
0.001
245 ± 15 212 ± 16 15.5 0.001 245 ± 22 215 ± 15 13.8 0.001
Data represented as mean ± SD, % d is the percentage difference in values for tibial subchondral bone between the control and MIA-injected knee. BV, bone
volume; BV/TV, bone volume fraction; MIA, monosodium iodoacetate; OA, osteoarthritis; OA-CTL, osteoarthritis control; SD, standard deviation; Tb.N, trabecular
number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness.
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Page 7 of 14were detected on the subchondral bone and along the
margins of the tibial plateau of the MIA-injected knee
(Figure 8E, F), indicating active bone formation, whereas
no such accumulation of fluorochrome labels was
detected in the control tibial plateau (Figure 8B, C).
Histology
All the rats showed articular cartilage degradation in the
tibia of the MIA-injected knee. The contralateral control
tibia had a smooth cartilage surface with evenly distribu-
ted chondrocytes, well-oriented and arranged in well-
ordered zones (Figure 9A). In the MIA-injected knee,
the severity of cartilage damage increased from the pos-
terior margin towards the center of the tibial plateau.
Proteoglycan loss was observed with Safranin O, and
showed greatly reduced cartilage staining in the center
of the tibial plateau. In the areas less affected by carti-
lage degradation there was partial cartilage damage. The
superficial layer was devoid of viable chondrocytes, and
disorganized chondrocyte clusters (chondrone) of vari-
able size were observed. There appeared to be prolifera-
tion of chondrocytes at the mid and deep cartilage
zones that extended into the subchondral bone area
(Figure 9B). Vertical fissures were observed at the super-
ficial cartilage zone that extended into the cartilage mid
and deep zone (Figure 9C). Coronal sections of the tibial
plateau showed cartilage fibrillation and delamination
(Figure 9D). These osteoarthritic changes were observed
in the medial tibial plateau, whereas the lateral tibial
plateau showed relatively mild cartilage changes. The
OARSI score of the medial tibial plateau in the MIA-
injected knee at 10 weeks was 17 ± 3 (mean ± SD). The
control tibia showed no OA activity (OARSI score 0).
In the MIA-injected knee, the subchondral bone was
sclerosed and exposed in the medial tibial plateau
beneath the areas of cartilage damage. Focally extensive
areas of subchondral bone marrow were replaced by
loosely arranged spindle cells (fibrotic bone marrow)
(Figure 9D). At six and ten weeks, the subchondral plate
was breached in focal areas, with cartilage damage and
proliferating chondrocytes at ten weeks suggesting fibro-
cartilage repair (Figure 5B). In four out of six rats, sub-
chondral bone cysts were observed below the articular
surface. These cysts were present in the sites of severe
bone resorption causing bone marrow lesions. The sub-
chondral bone cysts were surrounded by sclerotic bone
with fibrous tissue often containing debris of necrotic
bone trabeculae. Some trabeculae adjacent to the sites
of bone resorption were lined by a row of large reactive
osteoblasts (Figure 5D). Marginal tibial osteophytes were
observed in all the rats at ten weeks post-MIA injection
of the knee. Bone marrow spaces filled with fibrous cells
were observed in these osteophytes (Figure 6D).
Serum CRP levels
The serum CRP levels were not significantly different
between the MIA-injected rats and control rats at any
time-point. In addition, there was no significant differ-
ence between time points for each of the two groups. In
the MIA-injected rats, the mean ± SD concentrations
Figure 4 Coronal and axial micro-CT images of an MIA-injected tibia at two weeks (a), six weeks (b) and ten weeks (c) post injection,
together with a control tibia at ten weeks (d). The MIA-injected tibia showed altered subchondral bone architecture, with sclerosis on the
medial tibial compartment (M) (indicated by arrow) at six and ten weeks after injection, whereas the control tibia showed no sclerosis at ten
weeks. Micro-CT, micro-computed tomography; MIA, monosodium iodoacetate.
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Page 8 of 14were as follows: 204 ± 32 μg/ml, 201 ± 44 μg/ml, 190 ±
50 μg/ml, and 202 ± 7 μg/ml at pre-injection, 2, 6 and
10 weeks, respectively. For the control group the mean
± SD concentrations were as follows: 172 ± 42 μg/ml,
186 ± 24 μg/ml, 181 ± 34 μg/ml, and 212 ± 9 μg/ml at
pre-injection, 2, 6 and 10 weeks, respectively.
Discussion
This study characterized the temporal changes in the
tibial subchondral bone architecture in a low-dose MIA-
induced OA rat model using in vivo micro-CT. The
strength of this study is the use of a longitudinal study
design, which enabled the quantitative and qualitative
assessment of OA-related changes in the tibial subchon-
dral trabecular bone within the same animal over time.
This is the first in vivo study to examine subchondral
trabecular bone changes over time revealing a signifi-
cantly lower bone volume fraction at two weeks, fol-
lowed by subchondral bone sclerosis at six and ten
weeks, in the low-dose MIA-induced OA rat model.
The initial bone loss observed at two weeks, followed
by sclerosis during the progression of OA is consistent
with findings in other animal models of OA, such as the
anterior cruciate ligament transection (ACLT) in rats
[16], the canine model [17] and the collagenase-induced
murine model, and to human OA [18]. This initial bone
loss observed at two weeks in the low-dose MIA rat
model could have been due to transient unloading of the
MIA-injected knee. Previously, it had been shown that
MIA injection in the rat knee joint leads to concentration
related transient changes in hind paw weight distribution
[3,19]. In the MIA-injected knee, Tb.N was decreased
and Tb.Sp was increased relative to the control tibia at all
time points, which suggests an active process of subchon-
dral trabecular bone erosion. Together with the increases
in Tb.Th found at weeks six and ten, these findings indi-
cate that subsequent increased bone formation in the
MIA-injected knee resulted from subchondral trabecular
bone thickening. This strongly suggests a mechanism for
bone remodelling/modelling in the subchondral trabecu-
lar bone in OA [20].
It should also be noted that over time the tibial sub-
chondral BV, BV/TV, Tb.Th, Tb.N and Pl.Th increased,
Figure 5 Coronal micro-CT image (A) and histology section (B)
of tibia from an MIA-injected knee, showing subchondral plate
breach by the activated chondrocytes as a result of abnormal
repair, as indicated by arrows (A, B). Micro-CT image revealed
the presence of focal subchondral bone lesions in the medial tibial
plateau (C) at ten weeks post injection (rectangle). The safranin O
and fast green stained section of the MIA-injected knee at ten
weeks post injection (D) confirmed the presence of subchondral
bone cyst in the areas of bone lesions as predicted by micro-CT
image. The cysts were found to be surrounded by sclerotic bone
with fibrous tissue containing debris of necrotic bone. Note the
presence of large active osteoblasts (arrow) lining the trabeculae
adjacent to the sites of bone resorption. Original magnification ×
100. Micro-CT, micro-computed tomography; MIA, monosodium
iodoacetate.
Figure 6 Micro-CT coronal images of tibia from a control knee
(A) and a MIA-injected knee (C) at ten weeks post injection.
Micro-CT images revealed the presence of marginal tibial
osteophytes in all the rats in the MIA-injected knee (C, arrow),
whereas the control knee injected with saline showed no
osteophyte-like structure formation (A). The normal control tibia (B)
and the marginal tibial osteophytes in the MIA-injected knee (D,
arrow) were confirmed by histology at ten weeks post injection. The
osteophytes contained marrow spaces filled with fibrous bone
marrow cells. Original magnification × 40. Micro-CT, micro-
computed tomography; MIA, monosodium iodoacetate.
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Page 9 of 14whereas the Tb.Sp decreased, in both the MIA-injected
knee and the control knee (Figure 3). This is in part due
to the normal growth of the rats at baseline, reaching
skeletal maturity. Similar age-related changes (increases)
in volumetric bone mineral density (vBMD) due to the
effect of normal animal growth have been reported in
the high-dose MIA rat model [21] and ACLT model
[22]. However, in our study the use of the contralateral
tibia as an internal control eliminates inter-animal varia-
bility for age-related changes and weight.
Pathologic subchondral plate changes are recognized
as a characteristic feature of OA. Previous studies have
looked at the subchondral plate changes in animal mod-
e l so fO As u c ha sd o g s ,m i c e ,c y n o m o l g u sm a c a q u e s ,
guinea pigs, and rabbits but not in rat models of OA.
Figure 7 Three-dimensional surface rendering obtained from micro-CT images of a control knee (A) and of a MIA-injected knee (B) at
ten weeks after injection. The control knee maintained the subchondral plate integrity with a smooth contour (A). The MIA-injected knee
showed erosion and pitting of the tibial subchondral plate, which was more severe in the medial tibial plateau, as indicated by arrow (B). Micro-
CT, micro-computed tomography; MIA, monosodium iodoacetate.
Figure 8 Macroscopic images of a control tibia (A-C) and of a
MIA-injected tibia (D-F), at ten weeks post injection. The control
tibia (A) had no cartilage lesions on the medial compartment (M)
and lateral compartment of the tibial plateau, whereas the MIA-
injected tibia (D) had severe cartilage lesions on the medial tibial
plateau (M). Fluorochrome images of the MIA-injected tibia showed
accumulation of calcein and xylenol orange along the margins of
the tibial plateau (E, F), suggesting osteophyte formation whereas
there was no accumulation of fluorochrome labels along the
margins of control tibia (B, C). MIA, monosodium iodoacetate.
Figure 9 Coronal sections stained with Safranin O and fast
green of a control tibia (A) and of a MIA-injected tibia (B-D)
showing the cartilage on the medial tibial plateau, at ten
weeks post injection. The control tibia (A) showed normal healthy
cartilage with normally distributed chondrocytes. The MIA-injected
tibia (B) showed loss of proteoglycans, loss of viable chondrocytes,
chondrocyte proliferation (arrow), and chondrocyte cluster
formation of variable sizes (arrowhead). The cartilage showed
fibrillation, vertical fissures (C, arrow) and delamination (D). The
subchondral trabecular bone architecture was altered with sclerosed
bone (C) and the cellular bone marrow was replaced by loosely
arranged spindle cells in a fine fibrous stroma (D, arrow). Original
magnification ×100. MIA, monosodium iodoacetate.
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l o w e db ya ni n c r e a s ei nt h i c k n e s sh a sb e e nr e p o r t e di n
the ACLT animal models of OA [17,23,24] and collagen
induced OA in mice [13,18]. However, in the low-dose
MIA-injected OA animal model, we found an increase
in the subchondral plate thickness in the medial tibial
plateau at two and six weeks post injection. Such an
early increase in the subchondral plate thickness has
been previously reported in other animal models of OA
such as rabbits [25] and guinea pigs [26], and in studies
of hand and knee OA patients [27]. This early increase
in subchondral plate thickness observed in the MIA-
injected knee could be due to altered loading of the
affected knee joint. The thickened subchondral bone
could also be associated with progression of cartilage
degeneration. In our study, at ten weeks we did not
observe the expected increase in the tibial subchondral
plate thickness in the MIA-injected knee compared to
the control. This could be due to the tibial subchondral
plate breach observed in the MIA-injected knee. The
increased porosity of the tibial subchondral plate in the
MIA-injected knee compared to the control is in line
with previous literature [23,24]. This increase in porosity
is believed to play an important role in the communica-
tion between bone and cartilage during the pathogenesis
of OA.
In the present study, the involvement of the subchon-
dral trabecular bone structure after induction of OA
using low-dose MIA is clearly shown in a temporal
sequence. The two, six and ten week time points were
chosen to characterize early, intermediate and advanced
OA-related changes in the bone. Because previous stu-
dies using the high-dose MIA rat model have reported
the involvement of subchondral bone as early as two
weeks after injection [21], two weeks was chosen as the
early time point in this study. A minimum of four
weeks interval is recommended between scans [22],
hence, six and ten weeks were chosen as subsequent
time points. Given the paired study design, where the
contralateral knee was used as an internal control, we
prioritized the capture of early subchondral bone
changes at two weeks over acquiring baseline data.
Qualitative analysis of micro-CT images revealed sub-
chondral trabecular bone sclerosis at six and ten weeks
post-MIA injection in the medial tibial plateau (Figure
4). This thickening of the subchondral trabecular bone
was detected by the significant increases in trabecular
thickness at six and ten weeks. Subchondral trabecular
bone loss together with subchondral bone sclerosis sug-
gests increased osteoclastic and osteoblastic activity that
leads to altered subchondral bone remodelling [28].
In our study, micro-CT imaging revealed subchondral
plate breach at six and ten weeks post-MIA injection.
This was observed in areas of cartilage damage in all the
rats (Figure 5A, B). In the weight bearing regions of the
medial tibial plateau where the cartilage damage was
severe, microfractures were observed in the subchondral
plate that exposed the subchondral bone marrow to the
joint cavity. This could potentially allow synovial fluid
to enter the subchondral bone that triggers cystic cavity
formation [29]. Another study suggests that the
increased pressure between the delaminated joint sur-
face leads to joint erosion, with synovial breach as a sec-
ondary event [30]. A recent study of human OA
suggests that cysts may develop in pre-existing bone
marrow lesions [31]. The subchondral plate breach also
suggests fibrocartilage repair, which could be seen as a
discontinuity of the articular bony plate [14]. Januz et
al. have previously reported subchondral plate breach
and its association with subchondral bone sclerosis and
cyst formation in the MIA rat model [4]. In our study,
67% of the rats showed subchondral bone cysts in areas
of bone resorption (Figure 5C, D).
Another hallmark feature of OA is the presence of
osteophytes. In our study, marginal osteophytes were
observed from micro-CT images in all the rats at six
and ten weeks post-MIA injection. The neochondrogen-
esis of mesenchymal stem cells in the periosteum and
synovial lining has been suggested to be the precursor
for osteophyte formation [32]. It is still unclear if osteo-
phytes are simply a pathological phenomenon or a func-
tional adaptation in OA. Macroscopic UV illumination
of the MIA-injected knee indicated accumulation of
fluorochrome labels along the tibial joint margins and
beneath the articular cartilage, demonstrating active
osteophyte and subchondral bone formation in all the
rats (Figure 8). Such calcein label accumulation was
reported previously in an ACLT model for OA in rats
[16]. Further histomorphometric analysis of fluoro-
chrome double labels is required to elucidate the rate of
bone turnover in tibial subchondral trabecular bone in
the MIA-injected knee and control knee.
In the present study, we documented histological
changes in the cartilage of the medial tibial plateau at
ten weeks post-MIA injection, including loss of proteo-
glycans, chondrocyte necrosis, chondrocyte proliferation,
chondrone formation, cartilage fibrillation and delamina-
tion (Figure 9). Similar cartilage changes have been
reported in other animal models of OA [33,34]. In this
study, articular cartilage damage was analyzed only at
the end of the study (ten weeks). Analysis of cartilage
changes at two and six weeks would have provided a
longitudinal correlation between cartilage loss and sub-
chondral bone changes. However, the main aim of this
study was to track the changes in subchondral trabecu-
l a rb o n ea r c h i t e c t u r eo v e rt i m e .M o r e o v e r ,w eu s e da
longitudinal study design that allows monitoring of bone
changes over time in the same animal, and thus
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cross-sectional study design [5,6].
T oo u rk n o w l e d g e ,t h i si st h ef i r s ts t u d yt os h o w
serum levels of CRP in the low-dose MIA induced OA
in rats. CRP is an acute phase protein and is a useful
non-specific marker of inflammatory diseases [35]. In
our study, we have shown that the serum CRP levels of
MIA-injected rats do not differ significantly between the
baseline and subsequent time points. In addition, there
was no significant difference in CRP levels between the
low-dose (0.2 mg) MIA-injected rats and control rats at
any time point. This demonstrates that a single intra-
articular injection of low-dose MIA does not induce
marked systemic inflammation in this animal model of
OA. Some studies indicated that in human OA the
extent and severity of OA is associated with low-grade
systemic inflammation with elevated serum CRP levels
[36]. However, more recently, the Rotterdam Study-I,
the largest cohort study to date, concluded that acute
systemic inflammation is not present in OA and future
studies should focus on the local inflammation process
involved in OA [37].
It is hypothesized that in OA, cartilage matrix break-
down causes synovial inflammation and subsequent
changes in the knee joint [38]. In the low-dose MIA rat
model, the cartilage breakdown products could lead to
mild local inflammation and synovitis in the knee joint
that promotes subchondral bone changes. In our study,
we were unable to observe for the presence of infiltrated
local inflammatory cells as histology was performed only
on the tibia and not the whole knee joint. Previous stu-
dies using the high-dose MIA rat model have reported
the presence of acute inflammation characterized by
expansion of the synovial membrane with infiltrating
macrophages, neutrophils and plasma cells in the rat’s
knee joint one day after injection which resolved by day
s e v e n[ 1 9 , 2 8 ] .I nam o r er e c e n t study, increased activa-
tion of macrophages in the knee joint was reported in a
high-dose MIA (1 mg) rat model up to four weeks after
injection [39].
Although the low-dose MIA model mimics articular
cartilage and subchondral bone pathology of human OA,
like any other animal model of OA it does not fully mir-
ror human OA. Barve et al. (2007) reported that 0.2 mg
MIA induced a consistent matrix loss of approximately
35%, similar to the observed range of human OA sam-
ples. However, they found that the transcriptional simi-
larity between the MIA rat and human OA cartilage was
modest [40]. This modest similarity between rat and
human cartilage could have been due to a difference in
sampling site, sampling of lesion and non-lesion contain-
ing cartilage, stages of OA, and contamination of carti-
lage by underlying bone. Moreover, this study did not
look at the protein expression or post translational
modification that may demonstrate greater similarity
between MIA rat and human OA cartilage. Other factors
such as species variability, tissue heterogeneity and differ-
ences in underlying molecular mechanisms need to be
considered. The choice of an animal model of OA mainly
depends on the purpose of a study. The main purpose of
our study was to characterize a non-trauma animal
model that mimics tissue-level features of human OA,
which could be used to study the effect of disease modi-
fying OA drugs on cartilage and subchondral bone.
Conclusions
In summary, the changes in cartilage and subchondral
trabecular bone structure observed in the low-dose MIA
rat model reveal important pathologic features of human
OA and the temporal progression of the disease in the
tibial subchondral bone. The low-dose MIA induced OA
rat model mimics the human disease condition and
clearly demonstrates disease progression in the tibial sub-
chondral bone in a timely manner. This animal model is
suitable to study the effect of suitable therapeutic drugs
on cartilage and subchondral bone. In vivo micro-CT
enabled the temporal characterization of the changes in
subchondral bone architecture both quantitatively and
qualitatively in 3D. The changes in subchondral trabecu-
lar bone structure were found to be consistent with dis-
ease progression, as confirmed by end-stage histology. In
vivo micro-CT is a non-destructive imaging technique
that can be used in future studies to track changes in
subchondral bone structure in drug intervention studies
designed to slow the progression of OA in a non-trauma
low-dose MIA induced OA rat model.
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